These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 32917226)

  • 41. Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial.
    Park JW; Kim YJ; Kim DY; Bae SH; Paik SW; Lee YJ; Kim HY; Lee HC; Han SY; Cheong JY; Kwon OS; Yeon JE; Kim BH; Hwang J
    J Hepatol; 2019 Apr; 70(4):684-691. PubMed ID: 30529387
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety and efficacy of transarterial chemoembolization plus sorafenib for hepatocellular carcinoma with portal venous tumour thrombus.
    Pan T; Li XS; Xie QK; Wang JP; Li W; Wu PH; Zhao M
    Clin Radiol; 2014 Dec; 69(12):e553-61. PubMed ID: 25304928
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Prognosis of Hepatocellular Carcinoma Treated with Sorafenib in Combination with TACE.
    Kimura Y; Kaneko R; Yano Y; Kamada K; Ikehara T; Nagai H; Sato Y; Igarashi Y
    Asian Pac J Cancer Prev; 2020 Jun; 21(6):1797-1805. PubMed ID: 32592380
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sorafenib in combination with transarterial chemoembolization for hepatocellular carcinoma: a meta-analysis.
    Hu MD; Jia LH; Liu HB; Zhang KH; Guo GH
    Eur Rev Med Pharmacol Sci; 2016; 20(1):64-74. PubMed ID: 26813455
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comprehensive treatments for hepatocellular carcinoma with tumor thrombus in major portal vein.
    Ye HH; Ye JZ; Xie ZB; Peng YC; Chen J; Ma L; Bai T; Chen JZ; Lu Z; Qin HG; Xiang BD; Li LQ
    World J Gastroenterol; 2016 Apr; 22(13):3632-43. PubMed ID: 27053855
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ranking of transarterial and targeted therapies for advanced hepatocellular carcinoma in the era of immuno-oncology: A network meta-analysis of randomized sorafenib-controlled trials.
    An J; Han S; Kim HI; Shim JH
    Hepatol Commun; 2022 Oct; 6(10):2886-2900. PubMed ID: 35785525
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Transcatheter arterial chemoembolization after stopping sorafenib therapy for advanced hepatocellular carcinoma.
    Huang YK; Yen CL; Shiu SI; Lee SW; Chang PY; Yeh HZ; Lee TY
    PLoS One; 2017; 12(11):e0188999. PubMed ID: 29190692
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Role of transarterial chemoembolization in relation with sorafenib for patients with advanced hepatocellular carcinoma.
    Ha Y; Lee D; Shim JH; Lim YS; Lee HC; Chung YH; Lee YS; Park SR; Ryu MH; Ryoo BY; Kang YK; Kim KM
    Oncotarget; 2016 Nov; 7(45):74303-74313. PubMed ID: 27494871
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Patterns of sorafenib and TACE treatment of unresectable hepatocellular carcinoma in a Chinese population: subgroup analysis of the GIDEON study.
    Liu F; Meng Z; Shao G; Wang J; Wang Z; Yang J; Yip CS; He D
    Mol Biol Rep; 2017 Feb; 44(1):149-158. PubMed ID: 27981445
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma.
    Cabrera R; Pannu DS; Caridi J; Firpi RJ; Soldevila-Pico C; Morelli G; Clark V; Suman A; George TJ; Nelson DR
    Aliment Pharmacol Ther; 2011 Jul; 34(2):205-13. PubMed ID: 21605146
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy of apatinib in patients with sorafenib-transarterial chemoembolization refractory hepatocellular carcinoma: a retrospective study.
    Cao Y; Ouyang T; Xiong F; Kan X; Chen L; Liang B; Zheng C
    Hepatol Int; 2021 Oct; 15(5):1268-1277. PubMed ID: 34415515
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of treatment safety and patient survival in elderly versus nonelderly patients with advanced hepatocellular carcinoma receiving sorafenib combined with transarterial chemoembolization: a propensity score matching study.
    Hu H; Duan Z; Long X; Hertzanu Y; Tong X; Xu X; Shi H; Liu S; Yang Z
    PLoS One; 2015; 10(2):e0117168. PubMed ID: 25689846
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The therapeutic benefits of combined sorafenib and transarterial chemoembolization for advanced hepatocellular carcinoma.
    Lee SW; Lee TY; Peng YC; Yang SS; Yeh HZ; Chang CS
    J Dig Dis; 2020 May; 21(5):287-292. PubMed ID: 32315498
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Is transcatheter arterial chemoembolization plus sorafenib better than chemoembolization plus placebo in the treatment of hepatocellular carcinoma?
    Xie Y; Tian H; Xiang H
    Tumori; 2021 Aug; 107(4):292-303. PubMed ID: 32729385
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial.
    Chao Y; Chung YH; Han G; Yoon JH; Yang J; Wang J; Shao GL; Kim BI; Lee TY
    Int J Cancer; 2015 Mar; 136(6):1458-67. PubMed ID: 25099027
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Survival benefit of transarterial chemoembolization in patients with metastatic hepatocellular carcinoma: a single center experience.
    Bettinger D; Spode R; Glaser N; Buettner N; Boettler T; Neumann-Haefelin C; Brunner TB; Gkika E; Maruschke L; Thimme R; Schultheiss M
    BMC Gastroenterol; 2017 Aug; 17(1):98. PubMed ID: 28797231
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Early Sorafenib-related Biomarkers for Combination Treatment with Transarterial Chemoembolization and Sorafenib in Patients with Hepatocellular Carcinoma.
    Zhong BY; Ni CF; Chen L; Zhu HD; Teng GJ
    Radiology; 2017 Aug; 284(2):583-592. PubMed ID: 28263701
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Early prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization plus sorafenib.
    Meng XC; Chen BH; Huang JJ; Huang WS; Cai MY; Zhou JW; Guo YJ; Zhu KS
    World J Gastroenterol; 2018 Jan; 24(4):484-493. PubMed ID: 29398869
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Transarterial chemoembolization and sorafenib in hepatocellular carcinoma.
    Cabibbo G; Tremosini S; Galati G; Mazza G; Gadaleta-Caldarola G; Lombardi G; Antonucci M; Sacco R
    Expert Rev Anticancer Ther; 2014 Jul; 14(7):831-45. PubMed ID: 24850249
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Which is the best combination of TACE and Sorafenib for advanced hepatocellular carcinoma treatment? A systematic review and network meta-analysis.
    Feng F; Jiang Q; Jia H; Sun H; Chai Y; Li X; Rong G; Zhang Y; Li Z
    Pharmacol Res; 2018 Sep; 135():89-101. PubMed ID: 29959032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.